CVS Health (CVS) Reaches Proposed FTC Settlement on Insulin Pricing

robot
Abstract generation in progress

CVS Health Corporation (NYSE:CVS) has reached a proposed settlement with the Federal Trade Commission regarding insulin pricing, a process expected to finalize in the coming weeks. This development follows a recent upgrade of CVS stock to Outperform by Bernstein analyst Lance Wilkes and Aetna’s agreement to pay $117.7 million to resolve False Claims Act allegations related to Medicare Advantage payments. The company provides healthcare services across insurance, pharmacy, and health solutions segments in the United States.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments